Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162579 | 0.91 | S1PR2 (0.45) | S1PR2GPR119SLC2A1GRIA1LMNA | |
| SCHEMBL18162356 | 0.87 | S1PR2 (0.48) | S1PR2GPR119SLC2A1GRIA1LMNA | |
| SCHEMBL18162598 | 0.86 | S1PR2 (0.49) | S1PR2GPR119SLC2A1GRIA1LMNA | |
| SCHEMBL18153338 | 0.84 | S1PR2 (0.46) | S1PR2GPR119SLC2A1GRIA1LMNA | |
| SCHEMBL18162573 | 0.83 | S1PR2 (0.44) | S1PR2GPR119SLC2A1GRIA1LMNA | |
| SCHEMBL18153336 | 0.82 | GALR2 (0.49) | S1PR2GPR119GRIA1LMNATLR9 | |
| SCHEMBL18162441 | 0.80 | L3MBTL1 (0.40) | LMNA | |
| SCHEMBL18153380 | 0.79 | SMN1; SMN2 (0.53) | GPR119SLC2A1LMNAACHE | |
| SCHEMBL18153313 | 0.78 | TLR9 (0.45) | GPR119LMNATLR9ACHEPIK3CA | |
| SCHEMBL16651838 | 0.77 | GPR119 (0.62) | S1PR2GPR119GRIA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | S1PR2 4178/4885GPR119 3630/4885SLC2A1 4867/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | S1PR2 4178/4885GPR119 3630/4885SLC2A1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.